Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merrimack Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Locally advanced/unresectable or metastatic breast cancer
Eighteen years of age or above
Able to understand and sign an informed consent (or have a legal representative who is able to do so)
Measurable disease according to RECIST v1.1
ECOG Performance Score of 0 or 1
Adequate bone marrow, hepatic, renal and cardiac function
Willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM-302
You may not be if
Patients for whom potentially curative anticancer therapy is available
Active infection or fever \> 38.5°C during screening visits or on the first scheduled day of dosing
Symptomatic CNS disease
Known hypersensitivity to any of the components of MM-302 or who have had hypersensitivity reactions to fully human monoclonal antibodies
Received other recent antitumor therapy
Pregnant or breast feeding
Patients with any other medical or psychological condition, deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results
